Active ingredientTorcetrapibCat. No. P-T166-001CAS 262352-17-0Family · Pharmaceutical analytical standards
Torcetrapib
A CETP inhibitor studied to raise HDL cholesterol and reduce cardiovascular risk: first given to humans in 1999, its development was stopped in December 2006, during phase III. This family brings together the active ingredient.
Did you know?CETP acts as a cholesterol 'ferry': it moves cholesteryl esters from HDL to VLDL and LDL. By blocking it, torcetrapib raised HDL and lowered LDL.
Go to the active ingredient →Active ingredientTorcetrapibCat. No. P-T166-001CAS 262352-17-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.